KRAS mutations are also observed in digestive cancers other than PDAC and CRC: in gastric cancer (~5-10% of gastric adenocarcinomas, mainly in the intestinal subtype), esophageal cancer (more prevalent in adenocarcinoma than in squamous cells, particularly in association with Barrett’s esophagus), biliary tract cancer (often coexisting with FGFR and IDH1/2 mutations), and hepatocellular carcinoma (uncommon, with greater prominence of other pathways, such as Wnt/β-catenin and TP53).159–163. Here, TP53 is linked to colorectal carcinoma.